Motivations of Patients With Diabetes to Participate in Research

AJOB Empirical Bioethics

Volumn 5, Issue 4, 2014, Pages 14-21

  Geppert, Cynthia ^a   Candilis, Philip ^b   Baker, Stephen ^b   Lidz, Charles ^b   Appelbaum, Paul ^c   Fletcher, Kenneth ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Columbia University ^*  (United States)

Author keywords

bioethics; diabetes; empirical ethics; general medical research; research participation; research subject motivations

Indexed keywords

EID: 84907302838     PISSN: 23294515     EISSN: 23294523     Source Type: Journal    
DOI: 10.1080/23294515.2014.910282     Document Type: Article

References (32)

1. Appelbaum, P. S., and T. Grisso. 2001. MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research. Sarasota, FL: Professional Resource Press.
2. Bentley, J. P., and P. G. Thacker. 2004. The influence of risk and monetary payment on the research participation decision making process. Journal of Medical Ethics 30(3): 293-298.
3. Bunnik, E. M., M. H. Schermer, and A. C. Janssens. 2012. The role of disease characteristics in the ethical debate on personal genome testing. BMC Medical Genomics 5: 4. doi:10.1186/1755-8794-5-4
4. Buscariollo, D. L., M. A. Davidson, M. Black, W. E. Russell, R. L. Rothman, and D. J. Moore. 2012. Factors that influence parental attitudes toward enrollment in type 1 diabetes trials. PLoS One 7(8): e44341. doi:10.1371/journal.pone.0044341
5. Candilis, P. J., K. E. Fletcher, C. M. Geppert, C. W. Lidz, and P. S. Appelbaum. 2008. A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects. Schizophrenia Research 99(1-3): 350-358.
6. Candilis, P. J., C. M. Geppert, K. E. Fletcher, C. W. Lidz, and P. S. Appelbaum. 2006. Willingness of subjects with thought disorder to participate in research. Schizophrenia Bulletin 32(1): 159-165.
7. Cassileth, B. R., E. J. Lusk, D. Guerry, et al. 1991. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. New England Journal of Medicine 324(17):1180-1185.
8. [Diabetes Control and Complications Trial]. 1999. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22(1): 99-111.
9. Folstein, M. F., S. E. Folstein, and P. R. McHugh. 1975. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12(3): 189-198.
10. Freeman, G. H., and J. H. Halton. 1951. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 38: 141-149.
11. Haga, S. B. 2009. Ethical issues of predictive genetic testing for diabetes. Journal of Diabetes Science and Technology 3(4): 781-788.
12. Hamann, J., B. Neuner, J. Kasper, et al. 2007. Participation preferences of patients with acute and chronic conditions. Health Expectations 10(4): 358-363. doi:10.1111/j.1369-7625.2007.00458.x
13. Hosmer, D. W., and S. Lemeshow. 1989. Applied logistic regression. New York, NY: John Wiley & Sons.
14. Huber, O., C. Beutter, J. Montoya, and O. W. Huber. 2001. Risk-defusing behavior: Towards and understanding of risky decision-making. European Journal of Cognitive Psychology 13: 409-426.
15. Kaminsky, A., L. W. Roberts, and J. L. Brody. 2003. Influences upon willingness to participate in schizophrenia research: An analysis of narrative data from 63 people with schizophrenia. Ethics and Behavior 13(3): 279-302.
16. Lawton, J., A. Fox, C. Fox, and A. L. Kinmonth. 2003. Participating in the United Kingdom Prospective Diabetes Study (UKPDS): A qualitative study of patients' experiences. British Journal of General Practice 53(490): 394-398.
17. Lidz, C. W., A. Meisel, M. Osterweis, J. L. Holden, J. H. Marx, and M. R. Munetz. 1983. Barriers to informed consent. Annals of Internal Medicine 99(4): 539-453.
18. Mouton, C., J. M. Teno, V. Mor, and J. Piette. 1997. Communication of preferences for care among human immunodeficiency virus-infected patients. Barriers to informed decisions? Archives of Family Medicine 6(4): 342-347.
19. National Diabetes Information Clearinghouse (NDIC). 2011. National diabetes statistics. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM_Statistics_508.pdf
20. Palmer, B. W., L. B. Dunn, P. S. Appelbaum, et al. 2005. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: Comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Archives of General Psychiatry 62(7): 726-733.
21. Reynolds, W. W., and R. M. Nelson. 2007. Risk perception and decision processes underlying informed consent to research participation. Social Science and Medicine 65(10): 2105-2115. doi:10.1016/j.socscimed.2007.06.021
22. Roberts, L. W., T. D. Warner, J. L. Brody, B. Roberts, J. Lauriello, and C. Lyketsos. 2002. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: Assessment of harm potential and factors influencing participation decisions. American Journal of Psychiatry 159(4): 573-584.
23. Roberts, L. W., T. D. Warner, K. A. Green Hammond, and C. M. Geppert. 2006. Perspectives on medical research involving men in schizophrenia and HIV-related protocols. Schizophrenia Bulletin 32(2): 360-365.
24. Roberts, L. W., T. D. Warner, K. D. Nguyen, C. D. Geppert, M. D. Rogers, and B. D. Roberts. 2003. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology (Berl.) 171(1): 58-67.
25. Robiner, W. N., J. A. Yozwiak, D. L. Bearman, T. D. Strand, and K. R. Strasburg. 2009. Barriers to clinical research participation in a diabetes randomized clinical trial. Social Science and Medicine 68(6): 1069-1074. doi:10.1016/j.socscimed.2008.12.025
26. Siegel, S. 1956. Nonparametric statistics for the behavioral sciences. New York, NY: McGraw-Hill.
27. Spilker, B., and J. A. Cramer. 1992. Patient recruitment in clinical trials. New York, NY: Raven Press.
28. Tarone, R. E. 1985. On heterogeneity tests based on efficient score. Biometrika 72: 91-95.
29. Tomamichel, M., C. Sessa, S. Herzig, et al. 1995. Informed consent for phase I studies: Evaluation of quantity and quality of information provided to patients. Annals of Oncology 6(4): 363-369.
30. Wainwright, S. P., C. Williams, M. Michael, B. Farsides, and A. Cribb. 2006. Ethical boundary-work in the embryonic stem cell laboratory. Sociology of Health and Illness 28(6): 732-748. doi:10.1111/j.1467-9566.2006.00539.x.
31. Ware, J. E., Jr., and C. D. Sherbourne. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 30(6): 473-483.
32. Winkelmann, B. R. 2003. Pharmacogenomics, genetic testing and ethnic variability: Tackling the ethical questions. Pharmacogenomics 4(5): 531-535. doi: 10.1517/phgs.4.5.531.23801